申请人:——
公开号:US20020107277A1
公开(公告)日:2002-08-08
The invention relates to a method of antagonizing GLP-1 activity in a mammalian patient, comprising administering to said patient an effective amount of a compound of the general formula I:
1
wherein
R
1
and R
2
independently of each other are C
1-4
-alkyl,
R
3
is halogen, hydroxy, C
1-4
-alkoxy or trifluoromethoxy,
R
4
is hydrogen, hydroxy or C
1-4
-alkoxy,
or a pharmacologically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising a compound of formula I.
本发明涉及一种拮抗哺乳动物患者体内 GLP-1 活性的方法,包括向所述患者施用有效量的通式 I 化合物:
1
其中
R
1
和 R
2
独立地为 C
1-4
-烷基、
R
3
是卤素、羟基、C
1-4
-烷氧基或三氟甲氧基、
R
4
是氢、羟基或 C
1-4
-烷氧基、
或其药理学上可接受的盐。本发明还涉及一种药物组合物,其中包含式 I 的化合物。